About

“The ultimate challenge for many drug developers is to develop advanced target discovery and validation strategies”.

This is what drug target leaders are saying to us. With continued high rates of efficacy and safety failures in the clinic, drug developers need to employ better target strategies to ultimately reduce drug attrition in the clinic and deliver better therapies to market.

But how do you expand your drug discovery and development capabilities? Where should drug developers deploy their resources? How do you generate commercially differentiated products?

These are just some of the questions that leading drug developers Pfizer, UCB Pharma, Bayer and Merck amongst others are debating, and will form the backbone of the World Drug Targets Summit agenda. This cutting edge meeting will provide a great blend of senior executives and scientists from pharma/biotech companies and academia in the field to discuss different target identification and validation strategies.

What’s covered on the agenda?

1. Assess key validation strategies with Novartis, Pfizer,  Merrimack Pharmaceuticals and Gilead Sciences
2. Hear Infinity Pharmaceuticals and UCB Pharma talk about what makes a good target and how to recognize targets which will lead to commercially differentiated products
3. Gain detailed insights from Bayer and Tempero Pharmaceuticals – A GSK Company into the importance of increased collaboration and scientific synergy within industry
4. Delve into the challenges and strategies to identify targets in the key therapeutic areas of oncology, respiratory and CNS Disorders withAstraZeneca, Pfizer, Harvard Medical School, Merck and Boehringer Ingelheim
5. Find out about methods to go after undruggable targets from Amgen, NeurAxon and FORMA Therapeutics
6.  Explore translational approaches to biomarker discovery, pathway understanding and target validation with AstraZeneca and Roche

And much more, click here to download the draft agenda

Featured Speakers

• 

  Khusru AsadullahVice President, Head of Target Discovery Bayer Schering Pharma AG

• 

  Fiona ThomsonTarget ID & Validation Lead Neuroscience Merck

• 

  Lorenz MayrExecutive Director, Unit Head Biology Novartis

• 

  Attila SeyhanBiomarker Discovery and Development Leader Pfizer

• 

  David WinklerResearch Associate Director Infinity Pharmaceuticals

• 

  Jeff ReaganScientific Director, Metabolic Disorders Amgen

• 

  Mike ZindaAssociate Director, AstraZeneca